Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

July 18, 2017

Agent Orange’s Possible Link to Rare Cancer Type Sparks Advocacy Efforts

Author(s):

Brielle Urciuoli

Exposure to Agent Orange — a toxic chemical combination used for deforestation during the Vietnam War — may be the cause of myeloproliferative neoplasms (MPNs) for hundreds of war veterans, according to MPN Advocacy and Education International.

“There was evidence very early that its use to exfoliate the jungle in Vietnam and other parts of the territory was having a grave impact on the health and safety of those exposed, including civilians,” Ann Brazeau, CEO of MPN Advocacy Network and Education International said in an interview with CURE.

Currently, MPNs are not on the Veterans Health Administration’s presumptive list, which means that veterans with MPNs such as essential thrombocytopenia (ET), polycythemia vera (PV) or myelofibrosis do not get disability benefits from the VA because it does not see those conditions as a direct result of their wartime service. Brazeau and her team are working to add MPNs to this list to help people like Barry Halem, of the Tampa Bay area — one of more than 500 veterans who contacted MPN Advocacy and Education International after developing an MPN.

“That’s too many for me to believe that it’s all a coincidence,” Halem said in an interview with CURE, referring to the known number of Vietnam veterans with MPNs. “The only thing we have in common is service in Vietnam.”

After coming home from Vietnam, where he worked on petroleum pipelines and storage tanks, Halem remained very active, running almost every day. Being in such good shape, he was surprised when he had a heart attack. Everything in his bloodwork looked fine except for a high platelet count. After seeing a hematology specialist 17 years ago, Halem received his diagnosis: ET.

The U.S. Department of Veterans Affairs has linked exposure to Agent Orange, which included the endocrine disrupter dioxin, to a number of cancers. They are: chronic B-cell leukemias, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, prostate cancer, respiratory cancers (including lung cancer) and soft tissue sarcoma.

Since his diagnosis, Halem has teamed up with MPN Advocacy and Education International in an effort to get MPNs added to the VA’s presumptive list. The organization’s efforts are ongoing and will include an event this Nov. 10 for Veteran’s Day, during which top professionals in the field — including Raajit Rampal, M.D., Ph.D., a hematologic oncologist from Memorial Sloan Kettering Cancer Center who is studying the possible correlatioin between Agent Orange and MPNs — will speak to veterans.

“We believe that it is not only essential to add MPNs to the VA’s presumptive list, but also to continue to research the link to Agent Orange/dioxin and improve the dialogue in the medical and health care community regarding chemical exposure and health issues,” Brazeau said. “The chemicals that made up the compound A/O-dioxin were referred to as the most toxic man-made chemicals produced.”

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctors with text.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of Dr. Tiziano Barbui
Image of doctor.
Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Image of Crispino
Picture of Joy Anderson
Image of doctor.
Dr. Richard “Rick" Winneker
Related Content
Advertisement
Image of doctor
June 21st 2025

What Patients With Polycythemia Vera Should Know After ASCO 2025

Dr. Joshua K. Sabari Dr. Raajit K. Rampal
Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about recent data from ASCO 2025.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Image of blood cells.
June 11th 2025

Rusfertide Reduces Phlebotomy Need, Improves Quality of Life in Polycythemia Vera

Ryan Scott
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
blood cells.
May 29th 2025

Pelabresib and Rituxan Combo Improves Outcomes in Myelofibrosis

Ryan Scott
A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial's primary end point for those with myelofibrosis.
Image of blood cells.
May 21st 2025

Evolving Myelofibrosis Treatments Aims to Fill Unmet Needs

Ryan Scott
JAK inhibitors ease symptoms in myelofibrosis, but only stem cell transplant offers a cure; newer drugs aim to fill unmet needs, especially for anemia.
Related Content
Advertisement
Image of doctor
June 21st 2025

What Patients With Polycythemia Vera Should Know After ASCO 2025

Dr. Joshua K. Sabari Dr. Raajit K. Rampal
Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about recent data from ASCO 2025.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Image of blood cells.
June 11th 2025

Rusfertide Reduces Phlebotomy Need, Improves Quality of Life in Polycythemia Vera

Ryan Scott
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
blood cells.
May 29th 2025

Pelabresib and Rituxan Combo Improves Outcomes in Myelofibrosis

Ryan Scott
A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial's primary end point for those with myelofibrosis.
Image of blood cells.
May 21st 2025

Evolving Myelofibrosis Treatments Aims to Fill Unmet Needs

Ryan Scott
JAK inhibitors ease symptoms in myelofibrosis, but only stem cell transplant offers a cure; newer drugs aim to fill unmet needs, especially for anemia.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.